VASCEPA's $4,200 Annual Cost Positioned Against New $40,000 Therapies
AMRN sits 23% above its 52-week low of $12.96.
Summary
Amarin is proactively reaffirming the role of its cardiovascular drug, VASCEPA, in the evolving triglyceride treatment landscape. The company highlights VASCEPA's proven efficacy, guideline support, and significantly lower annual wholesale acquisition cost of approximately $4,200, compared to $40,000 for recently approved injectable APOC3 therapies. This strategic communication follows the recent FDA approval of new APOC3 therapies and comes after Amarin's significant U.S. Supreme Court patent loss for Vascepa on June 4th. The substantial cost differential positions VASCEPA as a critical first-line option, especially given potential payer and PBM restrictions on premium-priced therapies. Future sales figures and payer coverage decisions for both VASCEPA and the new APOC3 therapies will indicate the effectiveness of this competitive positioning.
At the time of this announcement, AMRN was trading at $15.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $334M. The 52-week trading range was $12.96 to $20.90. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.